PinkDx

PinkDx is an early-stage diagnostics company focused on addressing unmet medical needs for women throughout their life journey. The company aims to identify clinical challenges that have not been adequately addressed before, preventing women from receiving optimal healthcare. PinkDx then applies a comprehensive, multi-omics approach and machine learning models to develop diagnostic tests that resolve these challenges.

For its initial indication, PinkDx plans to develop solutions to improve diagnostic outcomes for women presenting with vague symptoms such as bloating, pelvic pain, and abnormal bleeding, which could signal gynecological cancers. Each year, an estimated 1.5 million women in the US present with these general symptoms, and over 100,000 women are ultimately diagnosed with gynecological cancers as of 2024. PinkDx's diagnostics will aim to replace invasive and painful procedures, mitigating significant delays women often face in obtaining answers.

PinkDx's approach involves assembling a comprehensive collection of patient samples representing the broad array of patients encountered in real-world clinical practice. The company extracts extensive data from each sample, including genomic, medical history, clinical, and pathological outcome features. It then applies robust bioinformatic tools and machine learning models to develop tests that provide accurate results based on each woman's unique profile.

PinkDx was co-founded by Bonnie Anderson, who previously co-founded and served as CEO of Veracyte, known for pioneering the Afirma test for thyroid cancer. Anderson and her team aim to leverage their expertise in applying cutting-edge science to clinical problems to address challenges in women's healthcare.